These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 37934220)

  • 21. Pharmacotherapy for anxiety and comorbid alcohol use disorders.
    Ipser JC; Wilson D; Akindipe TO; Sager C; Stein DJ
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD007505. PubMed ID: 25601826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
    Rösner S; Leucht S; Lehert P; Soyka M
    J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.
    Bahji A; Bach P; Danilewitz M; Crockford D; Devoe DJ; El-Guebaly N; Saitz R
    J Addict Med; 2022 Nov-Dec 01; 16(6):630-638. PubMed ID: 35653782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
    Klemperer EM; Hughes JR; Naud S
    Drug Alcohol Depend; 2018 Sep; 190():229-234. PubMed ID: 30059816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acamprosate for the treatment of alcohol dependence.
    Boothby LA; Doering PL
    Clin Ther; 2005 Jun; 27(6):695-714. PubMed ID: 16117977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.
    Collins SE; Duncan MH; Saxon AJ; Taylor EM; Mayberry N; Merrill JO; Hoffmann GE; Clifasefi SL; Ries RK
    Lancet Psychiatry; 2021 Apr; 8(4):287-300. PubMed ID: 33713622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.
    Palpacuer C; Laviolle B; Boussageon R; Reymann JM; Bellissant E; Naudet F
    PLoS Med; 2015 Dec; 12(12):e1001924. PubMed ID: 26694529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alcoholics Anonymous and other 12-step programs for alcohol use disorder.
    Kelly JF; Humphreys K; Ferri M
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD012880. PubMed ID: 32159228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
    Zarkin GA; Bray JW; Aldridge A; Mitra D; Mills MJ; Couper DJ; Cisler RA;
    Arch Gen Psychiatry; 2008 Oct; 65(10):1214-21. PubMed ID: 18838638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
    Soyka M; Chick J
    Am J Addict; 2003; 12(s1):s69-s80. PubMed ID: 14972781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between medication adherence and treatment outcomes: the COMBINE study.
    Zweben A; Pettinati HM; Weiss RD; Youngblood M; Cox CE; Mattson ME; Gorroochurn P; Ciraulo D
    Alcohol Clin Exp Res; 2008 Sep; 32(9):1661-9. PubMed ID: 18616687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New pharmacotherapies for alcohol dependence.
    Graham R; Wodak AD; Whelan G
    Med J Aust; 2002 Jul; 177(2):103-7. PubMed ID: 12098353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acamprosate for alcohol dependence.
    Rösner S; Hackl-Herrwerth A; Leucht S; Lehert P; Vecchi S; Soyka M
    Cochrane Database Syst Rev; 2010 Sep; (9):CD004332. PubMed ID: 20824837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review.
    Hyland CJ; McDowell MJ; Bain PA; Huskamp HA; Busch AB
    J Subst Abuse Treat; 2023 Jan; 144():108919. PubMed ID: 36332528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medications for Alcohol Use Disorder.
    Poorman E; McQuade BM; Messmer S
    Am Fam Physician; 2024 Jan; 109(1):71-78. PubMed ID: 38227873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Extended-Release Injectable Naltrexone on Alcohol Use Disorder Treatment: A Systematic Review.
    Kedia SK; Ahuja N; Dillon PJ; Jones A; Kumar S; Satapathy S
    J Psychoactive Drugs; 2023; 55(2):233-245. PubMed ID: 35635191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence.
    Agabio R; Trogu E; Pani PP
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD008581. PubMed ID: 29688573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opioid antagonists for alcohol dependence.
    Rösner S; Hackl-Herrwerth A; Leucht S; Vecchi S; Srisurapanont M; Soyka M
    Cochrane Database Syst Rev; 2010 Dec; (12):CD001867. PubMed ID: 21154349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
    Maisel NC; Blodgett JC; Wilbourne PL; Humphreys K; Finney JW
    Addiction; 2013 Feb; 108(2):275-93. PubMed ID: 23075288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
    Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.